| 000 | 01424 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517172121.0 | ||
| 264 | 0 | _c20190503 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1398-9995 | ||
| 024 | 7 |
_a10.1111/all.13302 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCasale, T B | |
| 245 | 0 | 0 |
_aResponse to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. _h[electronic resource] |
| 260 |
_bAllergy _c02 2018 |
||
| 300 |
_a490-497 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Asthmatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAsthma _xdrug therapy |
| 650 | 0 | 4 |
_aBiological Products _xtherapeutic use |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOmalizumab _xtherapeutic use |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aChipps, B E | |
| 700 | 1 | _aRosén, K | |
| 700 | 1 | _aTrzaskoma, B | |
| 700 | 1 | _aHaselkorn, T | |
| 700 | 1 | _aOmachi, T A | |
| 700 | 1 | _aGreenberg, S | |
| 700 | 1 | _aHanania, N A | |
| 773 | 0 |
_tAllergy _gvol. 73 _gno. 2 _gp. 490-497 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/all.13302 _zAvailable from publisher's website |
| 999 |
_c27515594 _d27515594 |
||